Sun Pharmaceutical Industries Limited Overview
Pro stress-test →Sun Pharmaceutical Industries Limited manufactures, develops, and markets branded and generic formulations and Active Pharmaceutical Ingredients (APIs), and is the largest pharmaceutical company in India. The company reported consolidated revenues of ₹582 billion for FY26 (year ended March 31, 2026), growing 11.9% year-on-year.
Strategic Profile
Pro stress-test →Sun Pharma's diversified business mix—including India formulations (33% of revenue), emerging markets, US generics, and specialty medicines—enables balanced growth, with the company maintaining 8.4% market share as India's leading pharmaceutical player. The company is expanding its innovative product portfolio with US launches (Unloxcyt) and India introductions (Ilumya) to drive differentiated therapy offerings.
Competitive Landscape
Pro stress-test →Sun Pharma competes in global generic pharmaceuticals and specialty medicines against international majors and regional peers. In India, it holds the #1 market position with 8.4% share; in the US, it faces pricing pressure on generics from competitors; in emerging markets, it has outpaced regional peers with 21.6% growth in formulations (Q3 FY26).
Industry Context
Sun Pharmaceutical Industries Limited operates in Generic and specialty pharmaceuticals.
Key facts
Founded: 1993 · Headquarters: Mumbai, India · Employees: ~16,436 · Revenue: ₹582 billion (FY26) · Market cap: ₹4.57 trillion (approx.)